Randomized clinical trial of aztreonam and aminoglycoside antibiotics in the treatment of serious infections caused by gram-negative bacilli.
Abstract
Aztreonam was compared with aminoglycoside antibiotics (tobramycin and amikacin) in a randomized, prospective, clinical trial in serious infections caused by gram-negative bacilli (GNB). A total of 43 evaluable patients with 47 infected sites were treated with aztreonam, and 41 evaluable patients were treated with aminoglycosides for 43 infections. Of patients treated with aztreonam, 17 were bacteremic, as were 12 of those treated with aminoglycosides. Clinical and microbiologic response rates were similar, except that only 5 of 11 patients with pneumonia were considered to be clinically cured with aminoglycoside therapy, while 5 of 6 patients with pneumonia treated with aztreonam were cured. Renal impairment was observed in 9 of 54 patients who received aminoglycoside antibiotics, but in only 2 of 53 patients treated with aztreonam. Hearing impairment developed in one patient treated with tobramycin. Transient elevations of serum transaminase levels occurred in 9 of 53 patients treated with aztreonam and in only 2 of 54 aminoglycoside-treated patients. Diarrhea and superinfection occurred with equal frequency in both groups. Serum concentrations of bactericidal activity could not be correlated with the outcome of therapy. Aztreonam appears to have comparable clinical efficacy with aminoglycoside antibiotics for the treatment of serious infections caused by aerobic and facultative GNB. Its use as a single agent for the treatment of serious lower respiratory infections caused by GNB warrants further evaluation.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.3M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Adkinson NF, Jr, Saxon A, Spence MR, Swabb EA. Cross-allergenicity and immunogenicity of aztreonam. Rev Infect Dis. 1985 Nov-Dec;7 (Suppl 4):S613–S621. [PubMed] [Google Scholar]
- Greenberg RN, Reilly PM, Luppen KL, McMillian R, Bollinger M, Wolk SM, Darji TB, Noorani AA. Treatment of serious gram-negative infections with aztreonam. J Infect Dis. 1984 Nov;150(5):623–630. [PubMed] [Google Scholar]
- Henry SA, Bendush CB. Aztreonam: worldwide overview of the treatment of patients with gram-negative infections. Am J Med. 1985 Feb 8;78(2A):57–64. [PubMed] [Google Scholar]
- Lerner AM. The gram-negative bacillary pneumonias. Dis Mon. 1980 Nov;27(2):1–56. [PubMed] [Google Scholar]
- Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med. 1984 Oct;77(4):657–662. [PubMed] [Google Scholar]
- Neu HC, Labthavikul P. Antibacterial activity of a monocyclic beta-lactam SQ 26,776. J Antimicrob Chemother. 1981 Dec;8 (Suppl E):111–122. [PubMed] [Google Scholar]
- Newman TJ, Dreslinski GR, Tadros SS. Safety profile of aztreonam in clinical trials. Rev Infect Dis. 1985 Nov-Dec;7 (Suppl 4):S648–S655. [PubMed] [Google Scholar]
- Nolen TM, Phillips HL, Hall HJ. Comparison of aztreonam and tobramycin in the treatment of lower respiratory tract infections caused by gram-negative bacilli. Rev Infect Dis. 1985 Nov-Dec;7 (Suppl 4):S666–S668. [PubMed] [Google Scholar]
- Rodriguez JR, Ramirez-Ronda CH. Efficacy and safety of aztreonam versus tobramycin for aerobic gram-negative bacilli lower respiratory tract infections. Am J Med. 1985 Feb 8;78(2A):42–43. [PubMed] [Google Scholar]
- Sabath LD, Casey JI, Ruch PA, Stumpf LL, Finland M. Rapid microassay of gentamicin, kanamycin, neomycin, streptomycin, and vancomycin in serum or plasma. J Lab Clin Med. 1971 Sep;78(3):457–463. [PubMed] [Google Scholar]
- Schentag JJ, Vari AJ, Winslade NE, Swanson DJ, Smith IL, Simons GW, Vigano A. Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia. Am J Med. 1985 Feb 8;78(2A):34–41. [PubMed] [Google Scholar]
- Sculier JP, Klastersky J. Significance of serum bactericidal activity in gram-negative bacillary bacteremia in patients with and without granulocytopenia. Am J Med. 1984 Mar;76(3):429–435. [PubMed] [Google Scholar]
- Scully BE, Neu HC. Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa. Am J Med. 1985 Feb;78(2):251–261. [PubMed] [Google Scholar]
- Stratton CW, Reller LB. Serum dilution test for bactericidal activity. I. Selection of a physiologic diluent. J Infect Dis. 1977 Aug;136(2):187–195. [PubMed] [Google Scholar]
- Swabb EA. Review of the clinical pharmacology of the monobactam antibiotic aztreonam. Am J Med. 1985 Feb 8;78(2A):11–18. [PubMed] [Google Scholar]
- Weinstein MP, Stratton CW, Ackley A, Hawley HB, Robinson PA, Fisher BD, Alcid DV, Stephens DS, Reller LB. Multicenter collaborative evaluation of a standardized serum bactericidal test as a prognostic indicator in infective endocarditis. Am J Med. 1985 Feb;78(2):262–269. [PubMed] [Google Scholar]
- Weinstein MP, Stratton CW, Hawley HB, Ackley A, Reller LB. Multicenter collaborative evaluation of a standardized serum bactericidal test as a predictor of therapeutic efficacy in acute and chronic osteomyelitis. Am J Med. 1987 Aug;83(2):218–222. [PubMed] [Google Scholar]
- Wolfson JS, Swartz MN. Drug therapy. Serum bactericidal activity as a monitor of antibiotic therapy. N Engl J Med. 1985 Apr 11;312(15):968–975. [PubMed] [Google Scholar]